Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar ...

In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival ...

Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer ...

In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...

Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again ...

With the help of AI, AstraZeneca’s three-in-one inhaler Breztri has a new furry mascot to help it stand tall over the crowded ...

GSK, Roche and Novartis continued Big Pharma's dealmaking spree with Asian companies. Three midsized Asian biopharmas reached ...

Since the launch of the Medicare GLP-1 Bridge on July 1, over 500,000 seniors have utilized the program and together saved ...

Repatha, also known as evolocumab, was first approved by the FDA in 2015 to help patients lower their LDL, or “bad,” ...

Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah ...

About two years ago, a head-to-head progression-free survival win made Akeso and Summit Therapeutics’ ivonescimab—and the ...

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...